Overview of Pimef

Property	Description
Active ingredient	Cefepime hydrochloride
Form	Powder for Solution or Infusion
Pharmacological class	Fourth-Generation Cephalosporin (Antibiotic)
General purpose	Treating serious bacterial infections
Origin	Synthetic compound

Pimef is a potent, prescription-only medication centered on the active ingredient, Cefepime hydrochloride, used primarily to address serious bacterial infections. This compound is clinically recognized for its efficacy against resistant bacteria. It is classified within the beta-lactam antibiotic family and belongs to the advanced fourth-generation cephalosporin class, a designation that ensures its stability against destructive bacterial enzymes known as beta-lactamases.

What Type of Antibiotic is Pimef?

Pimef is a synthetic, single-component medication distinguished as a fourth-generation cephalosporin. Cefepime is characterized by its balanced broad-spectrum activity against both Gram-negative and Gram-positive bacterial strains, a hallmark of the fourth-generation subclass. Its chemical structure as a zwitterionic compound allows it to rapidly penetrate the cell walls of targeted bacteria, ensuring its swift bactericidal action.

The drug's mechanism involves disrupting the final stages of the bacterial cell wall synthesis. This highly effective mode of action provides the practical benefit of offering a rapid and definitive reduction of the microbial load, which is essential when managing critical infections.

Composition and Form of Cefepime

The physical form of Pimef is a Powder for Solution or a Solution for Infusion, meaning it must be administered by the parenteral route, specifically via Intravenous or Intramuscular Injection. This presentation is critical for its function, as the active ingredient, Cefepime hydrochloride, must be delivered directly into the bloodstream in a prepared aqueous solution.

Delivery via injection ensures that high, consistent concentrations of the medication reach the site of severe infection quickly, bypassing the variable absorption of the digestive system. This reliable administration method, paired with the drug's inherent broad-spectrum activity, is essential for maximizing its therapeutic impact and confirming its utility as a foundational agent in managing critical bacterial infections.

Regulatory References

What side effects are possible with Pimef?

Possible side effects and safety information for Pimef

Adverse Reaction Scope

The official safety profile for Pimef (Cefepime) is defined by its adverse reactions classified by frequency and System-Organ Class (SOC) as per regulatory documents. The medication is formally contraindicated in individuals with a history of immediate hypersensitivity to Cefepime, the cephalosporin class, penicillins, or other beta-lactam antibacterial drugs.

Frequency Classification: Reactions listed as Common (incidence 1%) include diarrhea, rash, and localized reactions (e.g., pain or inflammation) at the injection site. A Positive Coombs' Test (without hemolysis) is the most common laboratory finding. Effects such as oral thrush, nausea, vomiting, pruritus, and changes in renal markers (e.g., elevated BUN/Creatinine) are classified as Uncommon.
System-Organ Classes Involved: Adverse effects are documented across various systems, most notably Nervous System Disorders, Gastrointestinal Disorders, Blood and Lymphatic System Disorders, and Renal and Urinary Disorders.

Serious Adverse Reactions and Safety Patterns

Specific serious adverse reactions are documented in regulatory labeling:

Neurotoxicity: Serious, life-threatening, or fatal occurrences have been reported, including Encephalopathy (confusion, stupor, coma), Seizures, and Nonconvulsive Status Epilepticus. This risk is explicitly tied to accumulated drug exposure and is more frequent in patients with renal impairment.
Other Severe Risks: These include severe hypersensitivity reactions (e.g., Anaphylaxis and Toxic Epidermal Necrolysis) and potentially fatal Clostridioides difficile-associated diarrhea (CDAD), which can occur during or up to two or more months after treatment cessation.

Population-Specific Safety Considerations

Older adults are noted to be more susceptible to serious neurologic adverse reactions, especially when associated with unrecognized or unadjusted renal impairment. Concomitant use with nephrotoxic drugs may increase the risk of adverse effects on the kidney.

Connection to the Overall Safety Profile

The regulatory safety structure classifies both frequently encountered, non-severe effects and rare but critically important risks. This framework establishes that while gastrointestinal and skin reactions are common, the most significant safety concerns are neurological events and severe allergic reactions, with the risk of neurotoxicity directly amplified in the setting of impaired kidney function, which is often observed in older patients.

Overdose and Emergency Response

Overdose and when to seek help — Official Regulatory Information for Pimef

This section describes the potential manifestations of Pimef overdose and the official actions required, based strictly on government regulatory documentation.

Overdose Scope

Element	Description
Documented Manifestations	Overdose is strictly defined by the potential for neurotoxicity. Symptoms include encephalopathy (such as confusion, hallucinations, stupor, or coma), myoclonus, aphasia, and seizures, including nonconvulsive status epilepticus.
Life-Threatening Risk	Regulatory documents report the potential for life-threatening or fatal occurrences of neurotoxicity associated with accumulation of the drug.
Population-Specific Note	The risk of neurotoxicity is significantly higher in patients with renal impairment (reduced creatinine clearance), who may be susceptible to drug accumulation.

Emergency Action Required

Element	Description
Immediate Action	If symptoms of neurotoxicity are observed, the medication must be immediately discontinued, and appropriate supportive measures must be instituted.
When to Seek Help	Immediate medical attention must be sought if a patient exhibits signs of altered mental status, confusion, or decreased responsiveness, which are key indicators of a severe reaction.
Management Note	No specific antidote is known for Pimef overdose. Hemodialysis is the officially recommended procedure to aid in removing the drug from the bloodstream in overdose situations.

Therapeutic Uses of Pimef

What Pimef treats: Main Uses and Benefits

This treatment is commonly used in situations involving certain distressing symptoms associated with inflammatory or irritative states, such as atopic dermatitis (eczema). It is used in areas where additional symptomatic support is needed and is relevant for easing symptom clusters that may become intense or disruptive, specifically addressing persistent itching (pruritus), visible redness (erythema), and associated skin irritation.

The treatment is commonly used across conditions characterized by periods of heightened symptoms (flare-ups) in relevant patient groups. It is considered relevant for managing mild to moderate episodes of eczema. The general benefit helps maintain a sense of stability when symptoms are more noticeable and supports the patient during difficult episodes by easing distress.

“This approach helps address symptoms that become more disruptive during flare-ups and supports general well-being during symptomatic phases.”

Quick Fact: Relief for Pruritus and Erythema

This medication may assist with managing symptoms related to inflammatory or irritative states, particularly when these symptoms interfere with daily functioning and create noticeable physiological strain.

Eligibility and Restrictions for Use

Pimef (Cefepime) eligibility is defined by absolute contraindications, age limitations, and conditional use requirements, as stated in official regulatory documents.

Eligibility Scope

Category	Official Regulatory Statement
Populations for whom use is allowed	Adults (18 years and older) and pediatric patients from 2 months to 16 years of age.
Populations for whom use is not recommended	Pregnant women (unless clearly needed) and nursing mothers.
Populations for whom use is contraindicated	Patients with a known history of immediate hypersensitivity to Cefepime or to any other beta-lactam antibacterial drugs, such as penicillins or cephalosporins.
Age-related eligibility rules	Contraindicated in infants less than 2 months of age; safety and effectiveness are not established in this group.
Condition-specific eligibility rules	Use in patients with impaired renal function (Creatinine Clearance le 60 mL/min) is restricted and requires careful consideration.
Eligibility-related restrictions	Patients with impaired renal function, including older adults, require dose adjustment due to the risk of drug accumulation and potential neurotoxicity.

Connection to the overall eligibility profile: Regulatory documents establish absolute prohibitions based on documented hypersensitivity history, mandate conditional restrictions for use in patients with impaired renal function, and confirm non-eligibility for infants under 2 months of age.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Pimef

Property	Description
Medicinal product categories with documented interactions	Aminoglycoside Antibiotics; Potent Diuretics; Coagulation Modifiers; Non-enzymatic Urinary Glucose Testing Reagents.
Specific interacting medicines (if explicitly listed)	Aminoglycosides (class); Potent Diuretics (e.g., Furosemide).
Mechanistic basis of interactions (only if stated in label)	Pharmacodynamic interaction leading to additive toxicity (nephrotoxicity/ototoxicity); Pharmacokinetic impact (elevated exposure / reduced clearance) in renally compromised patients; Interference with laboratory diagnostic procedure.
Timing-based interaction rules (if applicable)	None explicitly mandated in regulatory labeling for mandatory temporal separation.
Population-specific interaction notes (if applicable)	Patients with renal impairment (CrCL le 60 mL/ min) must have dosage adjustments to mitigate toxic exposure risk. Geriatric patients with renal insufficiency are noted as a high-risk group for neurotoxicity from unadjusted doses.
Interaction-related restrictions	Non-enzymatic methods (copper reduction tests) for urinary glucose are restricted due to risk of false-positive results. Prothrombin time monitoring is advised for patients at risk of coagulopathy.

Interaction classifications (high-level)

Property	Description
Interaction severity classification (as defined in official documents)	Serious Pharmacodynamic Interaction Risk; Pharmacokinetic Risk (in specific populations); Diagnostic Test Interference.
Regulatory basis (EMA / FDA / etc.)	U.S. FDA Prescribing Information and consistent with NIH monographs.
Interaction-context constraints (as defined in official documents)	Monitoring of renal function is advised during concomitant administration of Potent Diuretics or Aminoglycosides.

Official interaction statements:

Aminoglycosides co-administration is officially documented to increase the potential risk of nephrotoxicity and ototoxicity.
Potent Diuretics require caution, as nephrotoxicity has been observed with concomitant use of other cephalosporins, and the label advises monitoring of renal function.
Urinary glucose tests using copper reduction methods may result in a false-positive reading, necessitating the use of enzymatic methods for accurate result classification.
A positive direct Coombs' Test has also been reported during treatment.

Connection to the overall interaction profile: The regulatory documents define Pimef's interaction structure primarily around additive pharmacodynamic toxicity risks with other renally eliminated drugs, in addition to laboratory test interference. Because elimination is predominantly renal, interaction profiles focus on clearance in compromised populations rather than CYP-mediated metabolic issues.

Mechanism of Action

Mechanism of PBP Covalent Inhibition

Pimef's core function is the immediate and irreversible chemical neutralization of essential bacterial Penicillin-Binding Proteins (PBPs). The drug utilizes a beta-lactam structure to mimic the natural PBP substrate. This interaction causes the beta-lactam ring to open, forming a stable covalent bond (acylation) with an active-site serine residue. This molecular action permanently disables the enzyme, leading directly to the arrest of the bacterial cell wall synthesis pathway.

Causal Cascade Leading to Cell Lysis

This mechanism describes the rapid cascade of molecular events that results in the destruction of the bacterial cell. By blocking the final transpeptidation step, the cell wall fails to cross-link, critically compromising the cell's osmotic stability. This structural failure subsequently triggers the bacteria's own autolytic enzymes, resulting in the rapid rupture and death of the microbial cell, thereby producing the bactericidal physiological effect.

Structural Evasion of Resistance Enzymes

This pathway highlights how Pimef's molecular structure contributes to its mechanism of action. The compound exhibits enhanced stability against hydrolysis by many common Extended-Spectrum beta-Lactamases (ESBLs) and AmpC beta-lactamases, which are enzymatic resistance factors. This structural feature facilitates target engagement and restricts enzymatic deactivation, allowing the PBP inhibition mechanism to proceed against these organisms.

Dosage and Administration Information

How Pimef is Used: Official Administration Guidelines

Pimef, which contains Cefepime hydrochloride, is administered only by the parenteral route—meaning it is not taken orally. The primary and most common method is Intravenous (IV) Infusion, typically administered over approximately 30 minutes. For specific, milder infections, the medicine may be given via Intramuscular (IM) Injection.

Since the drug is supplied as a sterile powder, it requires reconstitution and dilution with an approved solution (such as Sterile Water or 0.9% Sodium Chloride) by a healthcare professional before administration. This ensures the correct concentration is achieved for infusion or injection.

Dosing and Frequency Patterns

Dosage regimens are established based on the type and severity of the infection. Standard adult doses (with normal renal function) range from 1 g to 2 g. The typical frequency is every 12 hours (twice daily). For high-intensity treatment, such as the empiric therapy for febrile neutropenia, the dose is often 2 g administered every 8 hours (three times daily), with total daily dosing not to exceed 6 g.

Population-Specific Usage Rules

Renal Impairment: A mandatory dose adjustment is required for patients with reduced kidney function (creatinine clearance leq 60 mL/min). This typically involves reducing the dose or extending the interval between administrations.
Pediatric Patients: For children aged 2 months to 16 years, dosing is usually calculated based on weight, generally 50 mg per kg per dose, ensuring the amount does not exceed the recommended adult dose.

Treatment courses generally last between 7 and 10 days, although the duration is adjusted based on the specific type of infection being treated.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Pimef (Cefepime)

This overview summarizes the official research evidence, including clinical trials and authoritative reviews, used to evaluate Pimef (Cefepime). This information describes how the medicine has been studied by researchers, what outcomes were measured, and where scientific understanding may still be developing. It does not provide medical advice or instructions.

Evidence for Use in Severe Pneumonia and Complicated Infections

The research used to review Cefepime for its studied indications, such as severe pneumonia, complicated urinary tract infections (cUTI), and complicated intra-abdominal infections, is primarily derived from comparative Randomized Controlled Trials (RCTs).

What researchers studied: Researchers monitored key outcomes related to resolving the infection, including the clinical response rate and the microbiological eradication of the bacteria causing the illness. For complicated infections caused by certain resistant bacteria, Cefepime has been evaluated as part of newer combination drug regimens.

What the studies reported: Findings describe patterns observed in these clinical trial settings, reporting measurements related to pathogen eradication and resolution of acute symptoms. For complicated intra-abdominal infections, evidence often involves Cefepime being used alongside another agent.

Evidence for Empiric Therapy in Febrile Neutropenia

The research used to evaluate Cefepime when studied in the setting of initial therapy for febrile neutropenia is extensive. These studies monitored short-term outcomes such as the time to defervescence, the rate of therapeutic failure, and all-cause mortality.

What the studies reported: Research highlights changes measured during the short treatment period, reporting on patterns related to the overall response to the initial therapy. Regulatory re-evaluations described patterns where the data did not indicate a higher rate of all-cause mortality when compared to other therapies studied.

What remains uncertain: Despite the regulatory confirmation, some uncertainty remains due to the historical inconsistency in findings across different meta-analyses regarding mortality in this specific high-risk subgroup.

Evidence in Special Populations

Pediatric patients, ranging from infants to adolescents, were included in certain comparative trials for indications such as severe pneumonia and febrile neutropenia. Similarly, older adults were represented in trials for complicated urinary tract infections. Research for certain other special groups, such as patients with multiple pre-existing neurological conditions or those undergoing kidney replacement therapies, is often limited to smaller observational studies or is still emerging. While data exist for children and older adults in core indications, evidence quality varies across studies for some high-risk or specific comorbidity groups.

Long-Term Research and Follow-up Duration

Study designs for all major indications utilized short-term follow-up durations. The primary outcomes—such as clinical cure and microbiological eradication—were typically assessed by researchers in the trials either immediately at the end of the active treatment period or at a Test of Cure (TOC) visit a few weeks later. This focus means that the existing evidence provides limited information for long-term outcomes regarding the durability of the response or the risk of infection recurrence over many months or years.

Frequently Asked Questions (FAQ)

Common questions about Pimef (FAQ)

Q: Are there any known interactions between Pimef and routine vaccines?

A: Regulatory documents list specific interactions with certain medicinal products, such as aminoglycosides and potent diuretics. However, official information does not document specific interactions between Pimef and common routine vaccines.

Q: What happens if a person feels their condition has improved, should they stop using Pimef immediately?

A: Official patient instructions describe that Pimef is typically used for the full duration determined by a prescribing healthcare provider. This applies even if symptoms related to the infection begin to improve before the full course of medication is completed.

Q: Can I use Pimef on broken or inflamed skin?

A: Pimef is an injectable medication that is administered directly into a vein or a muscle by a healthcare professional. It is not available as a cream or ointment, and it is not intended for topical application to the skin.

Q: How does Pimef interact with common over-the-counter pain relievers like ibuprofen or acetaminophen?

A: Regulatory documents list interactions with specific prescription medicines, including certain diuretics and antibiotics that affect the kidneys. Official product information does not document specific interactions with common over-the-counter pain relievers like ibuprofen or acetaminophen.

Q: Are there warnings about using Pimef alongside products that contain alcohol?

A: Some official drug information advises that patients discuss the use of alcohol or tobacco with their healthcare provider. The discussion allows the healthcare provider to assess any potential effects related to a patient’s overall condition.

Q: Can Pimef cause allergic reactions?

A: Yes, Pimef is formally associated with the risk of hypersensitivity reactions, which are allergic responses. This includes the possibility of serious and life-threatening reactions such as anaphylaxis.

Q: If I have a history of skin infections, can I still use Pimef?

A: Pimef is approved for use in treating specific bacterial infections, including certain uncomplicated skin and skin structure infections. Decisions regarding treatment are based on a healthcare provider's review of a patient’s overall medical history, including any prior infections.

Q: Are there specific patient characteristics that make Pimef a better or worse option?

A: Regulatory documents explicitly note that patients with reduced kidney function (creatinine clearance le 60 mL/min) are at a greater risk for neurological side effects. For this reason, official guidelines mandate a dose adjustment for patients in this group.

Q: If a dose of Pimef is missed, should I apply it as soon as I remember or skip it?

A: Patient instructions generally advise that a missed dose may be administered as soon as it is remembered. To clarify the rules of spacing doses, official patient information describes conditions for when a missed dose may be skipped to maintain the correct interval and avoid a double administration.

Q: What should a patient do if they accidentally get Pimef in their eyes or mouth?

A: Official safety data sheets describe that if the product enters the eyes, irrigation with clean water for at least 15 minutes is advised. In the case of accidental ingestion or eye exposure, immediate medical attention is required.

Q: Can Pimef affect the results of a blood test or other lab work?

A: Yes, Pimef is known to interfere with certain laboratory tests. This includes potentially causing a false-positive result in urinary glucose tests that use copper reduction methods. A positive direct Coombs' Test, which checks for antibodies on red blood cells, has also been reported during treatment.

Q: What does it mean if Pimef is described as a second-line treatment?

A: Pimef is a fourth-generation cephalosporin, which is a class of antibiotic often used for serious or resistant bacterial infections. It is generally reserved for situations where narrower-spectrum antibiotics may not be effective.

Q: Can Pimef be used at the same time as UV light therapy?

A: Official handling instructions indicate the dry powder formulation of Pimef is stored protected from light to maintain its stability. Similarly, the prepared solution is protected from light during its administration.

Q: Is it normal to experience a flu-like feeling or headache when starting Pimef?

A: Official adverse reaction reports for Pimef list both headache and fever as reactions that may be experienced during treatment. Other general symptoms like chills or weakness may also occur.

Q: Are there specific instructions about applying other creams or cosmetics over Pimef?

A: Pimef is administered only by injection into a vein or muscle. Because of this route of administration, there are no specific official instructions or warnings regarding the topical use of creams or cosmetics in conjunction with this medication.

Q: If I am taking an herbal supplement, could it interact with Pimef?

A: Official drug labels list specific interactions with certain prescription medicines like potent diuretics. However, specific interactions with herbal supplements are not generally documented in the regulatory product information.

Q: Does the time of day a person applies Pimef matter?

A: The timing of Pimef administration is based on maintaining the correct interval between doses, such as every 8 or every 12 hours. Official instructions emphasize consistent spacing between doses rather than a dependence on a specific time of day.

Q: What happens if Pimef is applied to a large area of the body?

A: Pimef is strictly an injectable medication and is not intended for topical use on the skin. Official safety information only documents local reactions, such as pain or inflammation, that may occur at the injection site.

Q: How does Pimef relate to other similar-sounding drug names I see online?

A: Pimef is a brand name for the active ingredient Cefepime. Cefepime belongs to the cephalosporin class of antibiotics. Other drugs with similar-sounding names may be other antibiotics in the same class or different generic versions of Cefepime.

Q: Is Pimef available as a generic medicine?

A: Yes, the active ingredient in Pimef, Cefepime, is widely available as a generic drug under various trade names worldwide.

Q: How long does the tingling or burning side effect typically last after starting treatment?

A: The official drug label lists localized reactions, such as pain or inflammation at the injection site, as common side effects. While these effects are documented, the precise duration of such localized reactions is not typically specified in the regulatory summary.

Q: Does Pimef contain any animal products or is it vegan/vegetarian friendly?

A: Pimef is supplied as a sterile, dry mixture containing the active ingredient, Cefepime hydrochloride, and L-arginine. The general regulatory label does not disclose the specific source materials used for the ingredients, such as L-arginine.

How should Pimef be stored and disposed of?

How to Store and Dispose of Pimef (Cefepime Hydrochloride for Injection)

The storage and handling of Pimef powder and solution are strictly defined by regulatory documents to ensure product stability and sterility.

Official Storage and Stability Conditions

Product Form	Temperature and Protection	Stability Time Limit (Post-Mixing)
Dry Powder	Store at Controlled Room Temperature (20 C to 25 C). Keep in outer carton to protect from light.	Until expiry date.
Prepared Solution	Can be stored at Room Temperature or Refrigerated (2 C to 8 C).	24 hours (Room Temp) or 7 days (Refrigerated)

Handling and Disposal Mandates

Keep Pimef out of the sight and reach of children. The solution is for single use; any unused portion must be discarded. Disposal of the medicinal product and waste material must be conducted in accordance with local requirements and must not be put into wastewater or household trash.

Pimef